Back To Search Results


Editor: Brendan Kelley Updated: 5/2/2023 10:41:55 AM


Dexamethasone has a wide variety of uses in the medical field. As a treatment, dexamethasone has been useful in treating acute exacerbations of multiple sclerosis, allergies, cerebral edema, inflammation, and shock. Patients with conditions such as asthma, atopic and contact dermatitis, and drug hypersensitivity reactions have benefited from dexamethasone.[1] In endocrinology, dexamethasone has been found useful as a test for Cushing syndrome.[2] 

Off-label indications are as follows. Dexamethasone is useful in the treatment of chemotherapy-induced nausea and vomiting. It is also used in the prevention and treatment of altitude sickness. It has also been used in the treatment of spinal cord compression due to metastases in oncological cases.[3] 

Dexamethasone is recommended for severely ill patients with COVID-19 who are on supplemental oxygen or ventilatory support; however, clinicians should not use it to manage patients with mild to moderate COVID-19.[4]

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Dexamethasone is a potent glucocorticoid with very little if any, mineralocorticoid activity.[5] Dexamethasone’s effect on the body occurs in a variety of ways. It works by suppressing the migration of neutrophils and decreasing lymphocyte colony proliferation. The capillary membrane becomes less permeable, as well. Lysosomal membranes have increased stability. There are higher concentrations of vitamin A compounds in the serum, prostaglandin, and some cytokines (interleukin-1, interleukin-12, interleukin-18, tumor necrosis factor, interferon-gamma, and granulocyte-macrophage colony-stimulating factor) become inhibited. Increased surfactant levels and improved pulmonary circulation have also been shown with dexamethasone. Dexamethasone is metabolized by the liver and excreted in the urine mainly.

COVID-19 produces a hyperinflammatory state. Hence therapeutic effectiveness of dexamethasone is likely due to the broad anti-inflammatory activities of glucocorticoids.[6] In a clinical trial of hospitalized patients with COVID-19, the use of dexamethasone resulted in lower 28-day mortality among those receiving either mechanical ventilation or oxygen.[7]

Pharmacokinetics: According to the manufacturer's labeling, the pharmacokinetics of oral dexamethasone is dose-proportional between the dose range of 0.5 to 40 mg. 

  • Absorption: Dexamethasone median time to peak concentrations (Tmax) is 1 hour (range: 0.5 to 4 hours). A high-fat, high-calorie diet decreased C max by 23% of a single 20 mg dose of dexamethasone.
  • Distribution: Dexamethasone is about 77% bound to human plasma proteins in vitro.
  • Elimination: The mean terminal half-life of dexamethasone is 4 hours (18%), and oral clearance is 15.7 L/hr following a single dose of dexamethasone.
  • Metabolism: Dexamethasone is metabolized by CYP3A4.
  • Excretion: Renal excretion of dexamethasone is less than 10% of total body clearance. Less than 10% of dexamethasone is excreted in the urine.


Dexamethasone is available in various formulations. It is available in strengths ranging from 0.5 mg to 6 mg as a tablet. Other administration forms are an injectable suspension or an oral solution.[8]

  • Oral tablets: 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg, and 20 mg
  • Oral elixir or solution: 0.5 mg/5 mL
  • Oral concentrate: Dexamethasone Intensol: 1 mg/mL ( contains alcohol)
  • Injection dexamethasone sodium phosphate: 4 mg/mL, 20 mg/5 mL, 120 mg/30 mL, 10 mg/mL, 100 mg/10 mL

Adult Dosing

  • In treating inflammation, it is advisable to start with low doses of 0.75 mg/day, which may be titrated to 9 mg/day, with dosing divided into 2 to 4 doses throughout the day, which applies to intravenous, intramuscular, and oral administrations. Less may be used when directly administered to the lesion or tissue, with dosing ranging from 0.2 to 20 mg per day.[9]
  • For acute multiple sclerosis exacerbations, 30 mg oral daily doses for seven days are recommended, followed by one month of 4 to 12 mg daily doses.
  • As cerebral edema may be a life-threatening condition, aggressive treatment is necessary. The recommendation is for 10 mg of intravenous dexamethasone, followed by 4 mg of intramuscular administration, given every 6 hours. In this instance, it is necessary to titrate down over seven days to discontinue dexamethasone therapy.[10]
  • The regimen is 1 to 6 mg/kg of intravenous dexamethasone as a one-time bolus in treating circulatory shock. The clinician may substitute this regimen with 40 mg, given intravenously every 2 to 6 hours. Treatment with high-dose dexamethasone is not recommended beyond 2 to 3 days.
  • Research has shown that allergic reactions improve with a 6-day regimen beginning with 4 to 8 mg intramuscular injection on the first day. This dose is followed by oral doses on days 2 to 6, beginning with 1.5 mg every 12 hours for days 2 and 3, 0.75 mg every 12 hours for the third day, and finally, 0.75 mg daily for days 5 and 6. Therefore, the patient should be appropriately titrated by day 7 with no dosing necessary on day 7.
  • Patients with COVID-19 (severe COVID-19): 6 mg once daily for ten days.[11]
  • Cushing syndrome test begins with a low-dose test. There are two versions of this test: the standard two-day and the overnight tests.
    • A 0.5 mg oral dose of dexamethasone is given every 6 hours for two days with the standard test. Six hours after giving the final dose, serum cortisol levels are measured. The overnight test begins with a 1 mg oral dose of dexamethasone at 11:00 PM, with a second 1 mg oral dose at midnight. The following morning, serum cortisol levels are tested between 8:00 AM and 9:00 AM. The test is interpreted as positive screening for Cushing syndrome if the final cortisol reading is high, signaling that the more specific confirmative high dose dexamethasone suppression test should follow.
    • The high-dose dexamethasone suppression test has three forms: the standard 2-day, overnight, and intravenous (IV). With all three versions of the test, baseline serum cortisol levels need to be determined before commencing with the test. Baseline serum is measurable with a 24-hour urinary free cortisol test.[12] The standard 2-day test uses 2 mg of oral dexamethasone given every 6 hours for two days. During the 2-day exam, urine is collected and tested for free cortisol, and 6 hours after the final dose of dexamethasone, blood is drawn to measure the serum cortisol level. The overnight test begins with an 8 mg oral dose of dexamethasone at 11:00 PM. The following morning between 8:00 AM, and 9:00 AM, serum cortisol is measured. The IV test is the shortest of the tests. The patient receives one milligram of dexamethasone via continuous intravenous infusion hourly for 7 hours. Serum cortisol is measured at the end of 7 hours.

Use in Specific Population

Patients with Hepatic Impairment

No dosage adjustments are provided in the manufacturer’s labeling.

Patients with Renal Impairment

The effect of renal impairment on the pharmacokinetics of dexamethasone has not been studied.

Pregnancy Considerations

Corticosteroids, including dexamethasone, readily cross the placenta. Adverse developmental consequences, including orofacial clefts (cleft lip with or without cleft palate) and intrauterine growth restriction (IUGR), have been documented using corticosteroids during pregnancy. In animal studies, the administration of corticosteroids to pregnant animals during organogenesis resulted in structural abnormalities, embryo-fetal mortality, and growth alteration. Advise pregnant women of dexamethasone's potential risk to a fetus. Dexamethasone is administered with anti-myeloma products that can cause embryo-fetal harm and are contraindicated for use in pregnancy. Human Data suggests that dexamethasone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Multiple courses of antenatal dexamethasone had been associated with reduced birth weight, susceptibility to infections, and increased blood glucose levels in newborns. Neonatal hypoglycemia was also reported. Also, infants should be carefully observed for signs of hypoadrenalism with in-utero exposure to substantial doses of corticosteroids via maternal administration.

Breastfeeding Considerations

Systemically administered corticosteroids appear in human milk and interfere with endogenous corticosteroid production, suppressing growth. Therefore, instruct women not to breastfeed during treatment two weeks after the last dose. Dexamethasone can decrease basal serum prolactin and thyrotropin-releasing hormone-stimulated serum prolactin increase in nonnursing women.[13]

Adverse Effects

Although dexamethasone is generally well tolerated, it does have its drawbacks as a medication. The most frequently reported adverse effect by patients is the presence of insomnia after use. Other frequent adverse effects include acne, indigestion, fluid retention, electrolyte imbalances, weight gain, increased appetite, anorexia, nausea, vomiting, acne, agitation, and depression. There have been reports of adrenal suppression, arrhythmias, spermatogenic changes, glaucoma, hypokalemia, pulmonary edema, pseudotumor cerebri, and increased intracranial pressure.[14]

Steroid-induced osteonecrosis of the femoral head(long-term treatment).[15]

Hepatotoxicity: Likelihood score: A (well-established cause of liver injury when given in high doses, due to reactivation of hepatitis-B or a hepatocellular injury after high dose treatment.[16]


Dexamethasone use is contraindicated if patients have systemic fungal infections, hypersensitivity to dexamethasone, or cerebral malaria. Another contraindication is to administer live or live-attenuated vaccines during dexamethasone use. The immune system will be suppressed, placing the patient at risk of infection. It is still permissible to administer killed or inactivated vaccines. However, it bears mentioning that corticosteroids may attenuate immune response, and it is unpredictable if immunity develops.[17]

In patients with cirrhosis, diverticulitis, myasthenia gravis, renal insufficiency, or ulcerative diseases such as peptic ulcer disease or ulcerative colitis, it is important to use caution when prescribing dexamethasone.

Recommendations include using dexamethasone cautiously during pregnancy as there is an increased risk of oral cleft formation.

Clinical experience has shown that large doses can increase blood pressure. In patients with recent myocardial infarction, it is advised to caution as an increase in free wall rupture of the left ventricle has been reported using dexamethasone.

Suppression of the hypothalamus-pituitary-adrenal axis (HPA axis) occurs with use, and therefore the rapid withdrawal of dexamethasone is not recommended. It is important to gradually increase and decrease any corticosteroid due to its effect on the HPA axis.

Latent diseases such as fungal (candida, cryptococcus, pneumocystis), parasitic (toxoplasmosis, amebiasis, Strongyloides), and bacterial (mycobacterium, Nocardia) infections may become active due to suppression of the immune system.[18]

Steroid use may inhibit bone formation and may lead to the formation of osteoporosis. Therefore, caution is necessary when prescribing dexamethasone to populations at higher risk for osteoporosis.[19]


  • Serum electrolytes levels, blood pressure
  • Serum glucose levels, HbA1c[20]
  • Periodic eye examination (long term dexamethasone increases the risk of cataracts and glaucoma)[21]
  • Bone mineral density scans[22]
  • Creatine kinase levels (long term use of glucocorticoids such as dexamethasone predisposes to myopathy; weakness is primarily proximal)[23]


According to the manufacturer’s labeling information, the oral LD50 of dexamethasone in female mice is 6.5 g/kg. The intravenous formulation of dexamethasone has an LD50 of 794 mg/kg in female mice. In the case of overdosage, no specific antidote is available. Therefore, treatment is supportive and symptomatic.

Enhancing Healthcare Team Outcomes

Dexamethasone is widely prescribed by all clinicians (MD, DO, NP, and PA). However, it is essential to know that this potent steroid has many adverse effects and requires critical patient monitoring. In general, clinicians should avoid long-term prescriptions, and the drug is tapered quickly if the patient is improving. If chronic use is warranted, the clinician must educate the patient about the potential side effects of the steroid. Pharmacists should assist with medication reconciliation, explain the potential risks associated with long-term steroid therapy, and report any concerns to clinicians. In addition, nurses must monitor the patient for mood changes, development of osteoporosis, weight gain, hyperglycemia, electrolyte changes, and depression. Open communication among all healthcare team members will enhance patient outcomes and improve patient safety using dexamethasone. [Level 5]



Corssmit EPM, Dekkers OM. Screening in adrenal tumors. Current opinion in oncology. 2019 May:31(3):243-246. doi: 10.1097/CCO.0000000000000528. Epub     [PubMed PMID: 30844886]

Level 3 (low-level) evidence


Bano G, Mir F, Beharry N, Wilson P, Hodgson S, Schey S. A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1. International journal of endocrinology and metabolism. 2013 Winter:11(1):52-6. doi: 10.5812/ijem.6898. Epub 2012 Dec 21     [PubMed PMID: 23853621]

Level 3 (low-level) evidence


Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. The Lancet. Oncology. 2019 Mar:20(3):e142-e154. doi: 10.1016/S1470-2045(19)30031-2. Epub     [PubMed PMID: 30842058]

Level 2 (mid-level) evidence


Lamontagne F, Agarwal A, Rochwerg B, Siemieniuk RA, Agoritsas T, Askie L, Lytvyn L, Leo YS, Macdonald H, Zeng L, Amin W, da Silva ARA, Aryal D, Barragan FAJ, Bausch FJ, Burhan E, Calfee CS, Cecconi M, Chacko B, Chanda D, Dat VQ, De Sutter A, Du B, Freedman S, Geduld H, Gee P, Gotte M, Harley N, Hashimi M, Hunt B, Jehan F, Kabra SK, Kanda S, Kim YJ, Kissoon N, Krishna S, Kuppalli K, Kwizera A, Lado Castro-Rial M, Lisboa T, Lodha R, Mahaka I, Manai H, Mendelson M, Migliori GB, Mino G, Nsutebu E, Preller J, Pshenichnaya N, Qadir N, Relan P, Sabzwari S, Sarin R, Shankar-Hari M, Sharland M, Shen Y, Ranganathan SS, Souza JP, Stegemann M, Swanstrom R, Ugarte S, Uyeki T, Venkatapuram S, Vuyiseka D, Wijewickrama A, Tran L, Zeraatkar D, Bartoszko JJ, Ge L, Brignardello-Petersen R, Owen A, Guyatt G, Diaz J, Kawano-Dourado L, Jacobs M, Vandvik PO. A living WHO guideline on drugs for covid-19. BMJ (Clinical research ed.). 2020 Sep 4:370():m3379. doi: 10.1136/bmj.m3379. Epub 2020 Sep 4     [PubMed PMID: 32887691]


Brinks J, van Dijk EHC, Habeeb M, Nikolaou A, Tsonaka R, Peters HAB, Sips HCM, van de Merbel AF, de Jong EK, Notenboom RGE, Kielbasa SM, van der Maarel SM, Quax PHA, Meijer OC, Boon CJF. The Effect of Corticosteroids on Human Choroidal Endothelial Cells: A Model to Study Central Serous Chorioretinopathy. Investigative ophthalmology & visual science. 2018 Nov 1:59(13):5682-5692. doi: 10.1167/iovs.18-25054. Epub     [PubMed PMID: 30489628]


Sharma A. Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic data. Gene. 2021 Jul 1:788():145665. doi: 10.1016/j.gene.2021.145665. Epub 2021 Apr 19     [PubMed PMID: 33887367]


RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine. 2021 Feb 25:384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17     [PubMed PMID: 32678530]


Eckhard L, Jones T, Collins JE, Shrestha S, Fitz W. Increased postoperative dexamethasone and gabapentin reduces opioid consumption after total knee arthroplasty. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2019 Jul:27(7):2167-2172. doi: 10.1007/s00167-019-05449-8. Epub 2019 Mar 2     [PubMed PMID: 30826856]


Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, Veal G, Halsey C, Newell DR, Vormoor J, Irving JAE. Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. Haematologica. 2019 Sep:104(9):1804-1811. doi: 10.3324/haematol.2017.185975. Epub 2019 Jan 17     [PubMed PMID: 30655370]

Level 3 (low-level) evidence


Orton S, Censani M. Iatrogenic Cushing's Syndrome Due to Intranasal Usage of Ophthalmic Dexamethasone: A Case Report. Pediatrics. 2016 May:137(5):. pii: e20153845. doi: 10.1542/peds.2015-3845. Epub 2016 Apr 7     [PubMed PMID: 27244810]

Level 3 (low-level) evidence


Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Apr 27:():. doi: 10.1093/cid/ciaa478. Epub 2020 Apr 27     [PubMed PMID: 32338708]


Monreal JA, Duval F, Mokrani MC, Fattah S, Palao D. Differences in multihormonal responses to the dopamine agonist apomorphine between unipolar and bipolar depressed patients. Journal of psychiatric research. 2019 May:112():18-22. doi: 10.1016/j.jpsychires.2019.02.009. Epub 2019 Feb 19     [PubMed PMID: 30836201]


. Dexamethasone. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 30000826]


Polderman JAW, Farhang-Razi V, van Dieren S, Kranke P, DeVries JH, Hollmann MW, Preckel B, Hermanides J. Adverse side-effects of dexamethasone in surgical patients - an abridged Cochrane systematic review. Anaesthesia. 2019 Jul:74(7):929-939. doi: 10.1111/anae.14610. Epub 2019 Mar 1     [PubMed PMID: 30821852]

Level 1 (high-level) evidence


Wu X, Sun W, Tan M. Noncoding RNAs in Steroid-Induced Osteonecrosis of the Femoral Head. BioMed research international. 2019:2019():8140595. doi: 10.1155/2019/8140595. Epub 2019 Dec 23     [PubMed PMID: 31930139]


. Corticosteroids. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31643719]


Kolias AG,Edlmann E,Thelin EP,Bulters D,Holton P,Suttner N,Owusu-Agyemang K,Al-Tamimi YZ,Gatt D,Thomson S,Anderson IA,Richards O,Whitfield P,Gherle M,Caldwell K,Davis-Wilkie C,Tarantino S,Barton G,Marcus HJ,Chari A,Brennan P,Belli A,Bond S,Turner C,Whitehead L,Wilkinson I,Hutchinson PJ, Dexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial. Trials. 2018 Dec 4;     [PubMed PMID: 30514400]

Level 1 (high-level) evidence


Sun W, Wang D, Yu C, Huang X, Li X, Sun S. Strong synergism of dexamethasone in combination with fluconazole against resistant Candida albicans mediated by inhibiting drug efflux and reducing virulence. International journal of antimicrobial agents. 2017 Sep:50(3):399-405. doi: 10.1016/j.ijantimicag.2017.03.015. Epub 2017 Jun 30     [PubMed PMID: 28673609]


Briot K, Roux C. Glucocorticoid-induced osteoporosis. RMD open. 2015:1(1):e000014. doi: 10.1136/rmdopen-2014-000014. Epub 2015 Apr 8     [PubMed PMID: 26509049]


Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World journal of diabetes. 2015 Jul 25:6(8):1073-81. doi: 10.4239/wjd.v6.i8.1073. Epub     [PubMed PMID: 26240704]

Level 3 (low-level) evidence


Mohan R, Muralidharan AR. Steroid induced glaucoma and cataract. Indian journal of ophthalmology. 1989 Jan-Mar:37(1):13-6     [PubMed PMID: 2807493]


Blake GM, Fogelman I. Bone densitometry, steroids and osteoporosis. Current opinion in nephrology and hypertension. 2002 Nov:11(6):641-7     [PubMed PMID: 12394611]

Level 3 (low-level) evidence


Gupta A, Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian journal of endocrinology and metabolism. 2013 Sep:17(5):913-6. doi: 10.4103/2230-8210.117215. Epub     [PubMed PMID: 24083177]